Carl Richard Schmidt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Carl Richard Schmidt has a total of 311 co-authors. Here are the top co-authors by number of shared publications:
- Timothy Michael Pawlik
Department of Surgery The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center Columbus Ohio USA
14 shared publications - Eliza Wright Beal
Departments of Surgery and Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, USA
13 shared publications Ioannis Hatzaras
Department of Surgery New York University New York New York
8 shared publications- Shishir K. Maithel
Division of Surgical Oncology, Department of Surgery, Robert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School of Medicine Chicago IL USA
8 shared publications - George A. Poultsides
Department of Surgery, Stanford University, Stanford, CA, USA
7 shared publications Mark Bloomston
Department of Surgery, the Ohio State University, Columbus, OH, USA
7 shared publications
Latest Publications
- 31 December 2025
- Published by Wiley in Journal of Surgical Oncology
- Vol. 133 (2) , 177-185
Pretreatment CA19‐9 Predicts Survival in Pancreatic Cancer With Optimal Response to Neoadjuvant Therapy
Background and Objectives: Pancreatic ductal adenocarcinoma (PDAC) is characterized by limited survival rates, yet patients who achieve optimal CA19‐9 response to neoadjuvant therapy (NAT) exhibit improved survival. This study examines the association between initial CA19‐9 levels and survival in PDAC patients who achieved CA19‐9 normalization with systemic chemotherapy. Methods: A retrospective, multi‐institutional analysis of patients with resectable/borderline‐resectable PDAC, who underwent NAT and curative‐intent pancreatectomy at the University of Pittsburgh Medical Center, University of Texas Southwestern Medical Center, NorthShore University, and West Virginia University To contexualize thi between 2010 and 2022, was performed. CA19‐9 secretors (> 37 U/mL, with total bilirubin < 2) at diagnosis, with optimal response to NAT (normalization and > 50% drop in CA19‐9) were included. A cutoff for pre‐NAT CA19‐9 of 400 U/mL was determined to maximize sensitivity and specificity for survival benefit, and the cohort was accordingly divided into two groups. Kaplan–Meier and Cox proportional‐hazards models were used for univariate and multivariable analyses. Results: A total of 134 patients were included, 32 (23.9%) had a pre‐NAT CA19‐9 ≥ 400U/mL. DFS and OS were considerably higher among patients with pre‐NAT CA19‐9 < 400U/mL (median(95%CI) in months, DFS:19.8(16.0,33.4) versus 7.8(5.0,13.0); OS:49.0(34.5,70.7) versus 23.1(13.8,50.9)). On multivariable analysis, pre‐NAT CA19‐9 ≥ 400 U/mL was significantly associated with reduced DFS and OS (DFS:HR = 2.4, p = 0.001; OS:HR = 1.9, p = 0.028). Conclusion: In this select cohort of PDAC patients with optimal NAT response, pre‐NAT CA19‐9 ≥ 400U/mL is strongly associated with decreased DFS and OS.
- 31 December 2025
- Published by Wiley in Journal of Surgical Oncology
- Vol. 133 (2) , 177-185
Pretreatment CA19‐9 Predicts Survival in Pancreatic Cancer With Optimal Response to Neoadjuvant Therapy
Background and Objectives: Pancreatic ductal adenocarcinoma (PDAC) is characterized by limited survival rates, yet patients who achieve optimal CA19‐9 response to neoadjuvant therapy (NAT) exhibit improved survival. This study examines the association between initial CA19‐9 levels and survival in PDAC patients who achieved CA19‐9 normalization with systemic chemotherapy. Methods: A retrospective, multi‐institutional analysis of patients with resectable/borderline‐resectable PDAC, who underwent NAT and curative‐intent pancreatectomy at the University of Pittsburgh Medical Center, University of Texas Southwestern Medical Center, NorthShore University, and West Virginia University To contexualize thi between 2010 and 2022, was performed. CA19‐9 secretors (> 37 U/mL, with total bilirubin < 2) at diagnosis, with optimal response to NAT (normalization and > 50% drop in CA19‐9) were included. A cutoff for pre‐NAT CA19‐9 of 400 U/mL was determined to maximize sensitivity and specificity for survival benefit, and the cohort was accordingly divided into two groups. Kaplan–Meier and Cox proportional‐hazards models were used for univariate and multivariable analyses. Results: A total of 134 patients were included, 32 (23.9%) had a pre‐NAT CA19‐9 ≥ 400U/mL. DFS and OS were considerably higher among patients with pre‐NAT CA19‐9 < 400U/mL (median(95%CI) in months, DFS:19.8(16.0,33.4) versus 7.8(5.0,13.0); OS:49.0(34.5,70.7) versus 23.1(13.8,50.9)). On multivariable analysis, pre‐NAT CA19‐9 ≥ 400 U/mL was significantly associated with reduced DFS and OS (DFS:HR = 2.4, p = 0.001; OS:HR = 1.9, p = 0.028). Conclusion: In this select cohort of PDAC patients with optimal NAT response, pre‐NAT CA19‐9 ≥ 400U/mL is strongly associated with decreased DFS and OS.
- 5 September 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 223,p. e68371
Robotic-assisted Lateral Pancreaticojejunostomy for Chronic Pancreatitis
Chronic pancreatitis is a debilitating, benign inflammatory disorder that significantly alters a patient's quality of life. Pancreatic drainage procedures have long been demonstrated to be safe and feasible using laparoscopic and open surgical approaches but have largely been replaced by pancreaticoduodenectomy. Over the past several decades, perioperative outcomes using the robotic platform in hepatobiliary surgery have been rapidly improving and, in many cases, surpassing outcomes in open and laparoscopic approaches. In appropriately selected patients with pancreatic duct obstruction and without an inflammatory mass at the head of the pancreas, there remains a role for parenchymal-sparing operations that relieve recurrent pancreatitis but also limit endocrine and exocrine insufficiency. We present a robotic-assisted lateral pancreaticojejunostomy for a patient with recurrent pancreatitis in the setting of a pancreatic duct stricture. The intention of this manuscript is to provide fellowship-trained hepatobiliary surgeons with a concise and adoptable method for performing robotic-assisted lateral pancreatojejunostomy. This article demonstrates critical aspects of the operation performed in a minimally invasive, robotic fashion to treat recurrent acute/chronic pancreatitis.
- 5 September 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 223,p. e68371
Robotic-assisted Lateral Pancreaticojejunostomy for Chronic Pancreatitis
Chronic pancreatitis is a debilitating, benign inflammatory disorder that significantly alters a patient's quality of life. Pancreatic drainage procedures have long been demonstrated to be safe and feasible using laparoscopic and open surgical approaches but have largely been replaced by pancreaticoduodenectomy. Over the past several decades, perioperative outcomes using the robotic platform in hepatobiliary surgery have been rapidly improving and, in many cases, surpassing outcomes in open and laparoscopic approaches. In appropriately selected patients with pancreatic duct obstruction and without an inflammatory mass at the head of the pancreas, there remains a role for parenchymal-sparing operations that relieve recurrent pancreatitis but also limit endocrine and exocrine insufficiency. We present a robotic-assisted lateral pancreaticojejunostomy for a patient with recurrent pancreatitis in the setting of a pancreatic duct stricture. The intention of this manuscript is to provide fellowship-trained hepatobiliary surgeons with a concise and adoptable method for performing robotic-assisted lateral pancreatojejunostomy. This article demonstrates critical aspects of the operation performed in a minimally invasive, robotic fashion to treat recurrent acute/chronic pancreatitis.
- 26 July 2025
- Published by Springer Nature
- p. 79-91
Gastric Cancer
- 16 July 2025
- Published by Elsevier in The American Journal of Surgery
- Vol. 248, 116523
Exploring the role of quality of life in surgical decision making for patients undergoing pancreatectomy
- 16 July 2025
- Published by Elsevier in The American Journal of Surgery
- Vol. 248, 116523
Exploring the role of quality of life in surgical decision making for patients undergoing pancreatectomy
- 27 March 2025
- Published by Springer Nature
- p. 221-224
Hepatic Failure Secondary to HAI Pump Chemotherapy
- 27 March 2025
- Published by Springer Nature
- p. 221-224
Hepatic Failure Secondary to HAI Pump Chemotherapy
- Open Access
- 27 November 2023
- Published by Wiley in Journal of Surgical Oncology
- Vol. 129 (1) , 48-62
Recent advances for treatment of upper gastrointestinal malignancy
Recent prospective trials for esophageal cancer, gastric cancer, and gastrointestinal stromal tumor (GIST) are encouraging. This manuscript reviews selected recently published studies. Not surprisingly, immunotherapy dominates the current clinical trial landscape. However, targeted biologic therapies and standard chemotherapy remain critical to the treatment of gastric and esophageal cancer while imatinib remains the backbone for advanced or metastatic GISTs. For all three cancers, surgical resection remains important when intent of treatment is potential cure.
- 27 November 2023
- Published by Wiley in Journal of Surgical Oncology
- Vol. 129 (1) , 48-62
Open AccessRecent advances for treatment of upper gastrointestinal malignancy
Recent prospective trials for esophageal cancer, gastric cancer, and gastrointestinal stromal tumor (GIST) are encouraging. This manuscript reviews selected recently published studies. Not surprisingly, immunotherapy dominates the current clinical trial landscape. However, targeted biologic therapies and standard chemotherapy remain critical to the treatment of gastric and esophageal cancer while imatinib remains the backbone for advanced or metastatic GISTs. For all three cancers, surgical resection remains important when intent of treatment is potential cure.
- 21 October 2022
- Published by Wiley
- p. 1-14
Carcinoma of the Stomach
- 28 April 2022
- Published by Wiley in Journal of Surgical Oncology
- Vol. 125 (7) , 1077-1078
Innovations defining the future of gastric cancer—Introduction
- 28 April 2022
- Published by Wiley in Journal of Surgical Oncology
- Vol. 125 (7) , 1077-1078
Innovations defining the future of gastric cancer—Introduction
- 28 April 2022
- Published by Wiley in Journal of Surgical Oncology
- Vol. 125 (7) , 1183
Innovations defining the future of gastric cancer: Summary
- 28 April 2022
- Published by Wiley in Journal of Surgical Oncology
- Vol. 125 (7) , 1183
Innovations defining the future of gastric cancer: Summary